摘要
在髓系白血病中,急性早幼粒细胞白血病(acute promyelocytic leukemia,APL)对全反式维甲酸(all-trans retinoic acid,ATRA)特别敏感。几乎所有APL患者对ATRA治疗都有反应,ATRA通过刺激白血病细胞分化,诱导APL患者缓解。然而,随着长期单用ATRA,ATRA耐药已成为APL患者化疗失败的主要原因之一。目前,对ATRA耐药机制尚不完全清楚,本文将从信号通路、基因、蛋白和酶问题来阐述其耐药机制。
Among myeloid leukemias,the acute promyelocytic leukemia(APL)was found to be specifically sensitive to all-trans retinoic acid(ATRA),almost all APL patients respond to ATRA therapy.The ATRA induces remission of APL patients by stimulating the differentiation of the leukemia cells.However,with the long-term application of ATRA alone,ATRA resistance has become one of the main causes of chemotherapy failure in the patients with acute promyelocytic leukemia.At present,the mechanism of ATRA-resistance is not completely clear,this review discusses the mechanism of drug-resistance in terms of signal pathways,genes,proteins and enzyme.
作者
牛亚娜
刘文君
NIU Ya-Na;LIU Wen-Jun(Department of Pediatric Hematology and Oncology,PI Research Laboratory of Children’s Hematology and Oncology Affiliated Hospital of Southwest Medical University,Luzhou 646000,Sichuan Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2019年第6期2024-2029,共6页
Journal of Experimental Hematology
基金
四川省基础研究项目(14JC0193)
关键词
急性早幼粒细胞白血病
全反式维甲酸
耐药机制
acute promyelocytic leukemia
all-trans retinoic acid
mechanisms of resistance
